Recruiting PHASE3 INTERVENTIONAL 3-arm NCT05407636

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

Sponsor: AbbVie

Conditions AMD CNV Wet Age-related Macular Degeneration WetAMD nAMD wAMD

Interventions ABBV-RGX-314 Dose 1 ABBV-RGX-314 Dose 2 Aflibercept (EYLEA®)

Updated 12 times since 2022 Last updated: Sep 23, 2025 Started: Jan 13, 2022 Primary completion: Oct 31, 2026 Completion: Nov 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on AMD and CNV, this trial is actively recruiting participants. The trial is conducted by AbbVie and has accumulated 12 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Jul 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3

▶ Show 7 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE3
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Jun 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
REGENXBIO Inc.

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Arecibo, Puerto Rico , Asheville, United States , Austin, United States , Aylesbury, United Kingdom , Bakersfield, United States , Baltimore, United States , Barcelona, Spain , Bari, Italy , Beaufort, United States and 148 more locations